DexCom, Inc. $DXCM Shares Acquired by Yousif Capital Management LLC

Yousif Capital Management LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 0.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 53,429 shares of the medical device company’s stock after acquiring an additional 484 shares during the quarter. Yousif Capital Management LLC’s holdings in DexCom were worth $4,664,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Golden State Wealth Management LLC lifted its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the first quarter worth about $27,000. Anderson Financial Strategies LLC acquired a new stake in shares of DexCom during the first quarter worth about $37,000. Alpine Bank Wealth Management acquired a new stake in shares of DexCom during the first quarter worth about $40,000. Finally, Private Trust Co. NA lifted its holdings in shares of DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 1.2%

Shares of NASDAQ:DXCM opened at $65.41 on Thursday. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a market capitalization of $25.65 billion, a PE ratio of 45.42, a PEG ratio of 1.39 and a beta of 1.47. The business has a 50 day moving average of $73.79 and a two-hundred day moving average of $77.54. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Mizuho lifted their target price on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Piper Sandler lifted their target price on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Finally, Truist Financial decreased their price target on DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at $8,417,840. This represents a 1.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,849 shares of company stock valued at $564,733. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.